Product Introduction
Bioactivity


英文名: JAK-2/3-IN-3

描述: JAK-2/3-IN-3 (化合物 ST4j) 可用于研究淋巴源性疾病和白血病。JAK-2/3-IN-3 以时间和剂量依赖性的方式抑制JAK2的自磷酸化并诱导细胞凋亡。JAK-2/3-IN-3 是 JAK2/3 的有效抑制剂，对JAK2和JAK3的IC50值分别为 13.00 和 14.86 nM。

体外活性: JAK-2/3-IN-3 (0-100 μM; 72 h) specifically inhibits human erythroleukemia cells with low toxicity to the normal cells [1]. JAK-2/3-IN-3 inhibits human erythroleukemia TF1 cell growth via the JAK2/STAT5 signaling pathway [1]. JAK-2/3-IN-3 (15.53 μM; 24, 48, 72 h) induces cytotoxicity via apoptosis in a time-dependent manner in TF1 cells [1]. JAK-2/3-IN-3 (IC 25, IC 50, IC 75; 24 h) induces cytotoxicity via apoptosis in a dose-dependent manner in TF1 cells [1]. Apoptosis Analysis [1] Cell Line: TF1 cells Concentration: 15.53 μM Incubation Time: 24, 48, 72 h Result: Increased cells apoptotic by ～20%, ～40% and ～70%, after 24-, 48- and 72-h incubations, respectively. Increased cells apoptotic by ～15%, 20%, and 30% with concentration of IC 25, IC 50 and IC 75, respectively. Cell Cytotoxicity Assay [1] Cell Line: TF1, HEL, Vero and HepG2 cells Concentration: 0-100 μM Incubation Time: 72 h Result: Inhibited growth of TF1 and HEL cells, with IC 50 s of 15.53 and 17.90 μM. Showed low toxic to normal Vero cells and HepG2 cells (IC 50 of >100 μM in Vero cells and of >50 μM in HepG2 cells).

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year